IMMUNOASSAY FOR GLYCOALBUMIN WITH MONOCLONAL ANTIBODY

该项目的长期目标是制定一个简单，具体， 和快速免疫诊断测试来测量非酶促的 人血浆中的糖化白蛋白。 该测试将是ELISA构建体， 使用特异性识别糖化的单克隆抗体 白蛋白，一个指标的周围血糖浓度超过 前2-3周。 过去十年的临床研究 建立了对当前血糖水平的定期评估， 对建立和维持糖尿病的控制至关重要， 控制糖尿病在阻止糖尿病的发展方面是重要的。 糖尿病并发症和预防宫内和围产期 糖尿病母亲的婴儿死亡率。 监测的中流砥柱 糖尿病控制是测量血糖浓度和 某些循环蛋白质非酶促地 糖化的 已发现可用于测量的主要蛋白质 非酶糖化量是血红蛋白和白蛋白。 每2-3个月测量一次糖化血红蛋白，以客观评估 环境葡萄糖在前一时段期间被控制，而 糖蛋白可以在较短的时间间隔内测量，以检测和记录 控制更近时间相关性的改进或恶化。 然而，一直没有可靠的和具体的方法来定量 糖蛋白 该项目将实现发展这样一个 方法，使用独特的和高度特异性的单克隆抗体，创建于 我们的实验室，它可以识别白蛋白中的糖化表位， 不存在于其他血浆蛋白中，并且不与未糖化的 白蛋白。

The long term objective of this project is to develop a simple, specific, and rapid immunodiagnostic test to measure the amount of non-enzymatically glycated albumin in human plasma. The test will be an ELISA construct that employs a monoclonal antibody that specifically recognizes glycated albumin, an index of the ambient blood glucose concentrations over the preceding 2-3 weeks. Clinical investigations during the past decade have established that periodic assessment of the prevailing blood glucose level is essential to establishing and maintaining control of diabetes, and that control of diabetes is important in arresting the development of complications of diabetes and preventing intrauterine and perinatal mortality in infants of diabetic mothers. The mainstay of monitoring diabetic control is measurement of blood glucose concentration and of the extent to which certain circulating proteins have become nonenzymatically glycated. The major proteins for which it has been found useful to measure the amount of nonenzymatic glycation are hemoglobin and albumin. Glycohemoglobin is measured every 2-3 months for an objective evaluation of the ambient glucose control during that preceding period, whereas glycoalbumin can be measured at shorter intervals to detect and document improvement or deterioration in control of more recent temporal relevance. However, there has been no reliable and specific method to quantitate glycoalbumin. This project will realize the opportunity to develop such a method, using a unique and highly specific monoclonal antibody, created in our laboratory, that recognizes glycated epitopes residing in albumin but not in other plasma proteins and that does not react with unglycated albumin.